Features | Partner Sites | Information | LinkXpress
Sign In
GLOBETECH PUBLISHING
GLOBETECH PUBLISHING
JIB

MicroRNA Treatment Prevents Breast Cancer in Mouse Model

By BiotechDaily International staff writers
Posted on 15 Jan 2014
Image: Milk ducts in cancer-prone mice are packed with tumor cells (deep purple cells, shown by arrow), causing the ducts to grow fatter. However, milk ducts in mice treated with a gene-silencing nanoparticle remain mostly hollow (right, shown by arrows), like healthy ducts (Photo courtesy of Dr. Amy Brock, Harvard University Medical School).
Image: Milk ducts in cancer-prone mice are packed with tumor cells (deep purple cells, shown by arrow), causing the ducts to grow fatter. However, milk ducts in mice treated with a gene-silencing nanoparticle remain mostly hollow (right, shown by arrows), like healthy ducts (Photo courtesy of Dr. Amy Brock, Harvard University Medical School).
Mice that had been genetically engineered to develop breast cancer were protected from the disease by injections of nanoparticles containing a specific microRNA (miRNA) directly into their milk ducts.

Investigators at Harvard University Medical School (Boston, MA, USA) were looking for biomarkers to better identify and treat breast lesions at the earliest possible stage of development. Working with transgenic C3(1)-SV40TAg mice, they used computational gene network modeling to identify the HoxA1 (Homeobox A1) protein as a putative driver of early mammary cancer progression. Previous studies had shown the HOXA1 gene was repressed by the microRNA miR-10a.

MicroRNAs (miRNAs) are a small noncoding family of 19- to 25-nucleotide RNAs that regulate gene expression by targeting mRNAs in a sequence specific manner, inducing translational repression or mRNA degradation, depending on the degree of complementarity between miRNAs and their targets. Many miRNAs are conserved in sequence between distantly related organisms, suggesting that these molecules participate in essential processes. In fact, miRNAs have been shown to be involved in the regulation of gene expression during development, cell proliferation, apoptosis, glucose metabolism, stress resistance, and cancer.

The investigators hypothesized that the progression of breast cancer could be blocked by RNA interference (RNAi) therapy and set out to develop a targeted therapeutic delivery strategy. Initially, they found that silencing the HOXA1 gene in cultured mouse or human mammary tumor spheroids resulted in increased lumen formation, reduced tumor cell proliferation, and restoration of normal epithelial polarization.

When the HOXA1 gene was silenced in vivo via intraductal delivery of nanoparticles loaded with miRNA through the nipple of transgenic mice with early-stage disease, mammary epithelial cell proliferation rates were suppressed, loss of estrogen and progesterone receptor expression was prevented, and tumor incidence was reduced by 75%. These findings were published in the January 1, 2014, online edition of the journal Science Translational Medicine.

"The findings open up the possibility of someday treating patients who have a genetic propensity for cancer, which could change people's lives and alleviate great anxiety," said senior author Dr. Don Ingber, professor of vascular biology and bioengineering at Harvard University Medical School. "The idea would be start giving it early on and sustain treatment throughout life to prevent cancer development or progression."

"This work marks a milestone not just in breast cancer research, but in systems biology," said Dr. Ingber. "Combining computational, engineering, and biological approaches has led to a new way to identify drugs that prevent cancer development and progression."

Related Links:

Harvard University Medical School



comments powered by Disqus

Channels

Drug Discovery

view channel
Image: Synthetic ion transporters can induce apoptosis by facilitating chloride anion transport into cells (Photo courtesy of the University of Texas, Austin).

Experimental Drug Kills Cancer Cells by Interfering with Their Ion Transport Mechanism

An experimental anticancer drug induces cells to enter a molecular pathway leading to apoptosis by skewing their ion transport systems to greatly favor the influx of chloride anions. To promote development... Read more

Therapeutics

view channel
Image: Liver cells regenerated in mice treated with a new drug (right) compared with a control group (center) after partial liver removal. Healthy liver cells are shown at left (Photo courtesy of Marshall et al, 2014, the Journal of Experimental Medicine).

New Drug Triggers Liver Regeneration After Surgery

Investigators have revealed that an innovative complement inhibitor decreases complement-mediated liver cell death, and actually stimulates postsurgery liver regrowth in mice. Liver cancer often results... Read more

Lab Technologies

view channel

White-Matter Deficits Found in Codeine-Containing Cough Syrup Users

A magnetic resonance imaging (MRI) study of chronic users of codeine-containing cough syrups (CCS) has found deficits in specific regions of brain white matter and linked these changes with increased impulsivity in codeine-containing cough syrup users. These findings were consistent with findings from earlier research of... Read more

Business

view channel

Partnership Established to Decode Bowel Disease

23andMe (Mountain View, CA,USA), a personal genetics company, is collaborating with Pfizer, Inc. (New York, NY, USA), in which the companies will seek to enroll 10,000 people with inflammatory bowel disease (IBD) in a research project designed to explore the genetic factors associated with the onset, progression, severity,... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.